Pegasys Adds Hepatitis B Indication, But Not Superiority Claim Over Epivir
Executive Summary
Roche is highlighting Pegasys' limited duration of treatment relative to other hepatitis B therapies following approval of the supplemental indication
You may also be interested in...
Bristol Baraclude Will Be Available April 8; Premium Price Planned
Bristol-Myers Squibb's Baraclude (entecavir) will be available on pharmacy shelves April 8 following FDA approval of the hepatitis B therapy
Pegasys Gets HIV Co-Infection Claim; Market Expansion Moves Forward
Roche is looking to a new chronic hepatitis C indication for Pegasys in patients co-infected with HIV to expand its hepatitis market penetration
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011